Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex December 16, 2020 17:47 CET Non Regulatory Read more
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 December 9, 2020 13:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2021 November 27, 2020 16:00 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report November 11, 2020 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial November 9, 2020 10:00 CET Non Regulatory Read more
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial November 8, 2020 12:45 CET Regulatory Read more
Calliditas closes acquisition of a controlling interest in Genkyotex SA November 3, 2020 15:15 CET Regulatory Read more
Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 October 19, 2020 08:00 CET Non Regulatory Read more
The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 October 1, 2020 09:45 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics September 30, 2020 10:00 CET Regulatory Read more
First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon September 8, 2020 08:00 CET Non Regulatory Read more
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA August 13, 2020 07:00 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report August 11, 2020 14:00 CET Non Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 2, 2020 08:45 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 25, 2020 18:30 CET Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 24, 2020 22:45 CET Regulatory Read more
CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas June 22, 2020 08:00 CET Non Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 12, 2020 23:00 CET Regulatory Read more
Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States June 5, 2020 08:40 CET Regulatory Read more
Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75 June 1, 2020 13:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 26, 2020 12:00 CET Regulatory Read more
Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States May 14, 2020 15:00 CET Regulatory Read more
Calliditas provides a corporate business update in the context of the Covid-19 pandemic April 27, 2020 08:00 CET Non Regulatory Read more
Calliditas strengthens its US Commercial Organization April 1, 2020 08:00 CET Non Regulatory Read more
Calliditas moves its Annual General Meeting 2020 to June 25 March 30, 2020 14:00 CET Regulatory Read more
Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ) March 3, 2020 12:45 CET Regulatory Read more
Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ) January 31, 2020 08:30 CET Regulatory Read more
Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN January 22, 2020 08:00 CET Non Regulatory Read more
Calliditas submits draft registration statement for the listing of ADSs in the U.S. January 9, 2020 17:35 CET Regulatory Read more
